Herpes

Can monkeypox be asymptomatic?
A Belgian study published in Nature Medicine, which included 224 patient samples, discovered that three of four men with positive monkeypox virus test results reported that they were asymptomatic at the time of testing.
September 1, 2022
2022 07 13 19 56 4243 3 D Monkeypox Infecting Cell 400
Qiagen launches syndromic monkeypox test for research
QIAstat-Dx Viral Vesicular Panel RUO comes in cartridge form and runs on the company's QIAstat-Dx automated syndromic testing devices. The panel allows medical researchers to detect monkeypox in about one hour using PCR-testing technology.
August 15, 2022
2022 07 13 19 56 4243 3 D Monkeypox Infecting Cell 400
FDA clears DiaSorin's Simplexa varicella-zoster virus test
The assay detects varicella-zoster virus DNA in cutaneous and mucocutaneous swab specimens and is designed for use on the company's Liaison MDX platform. It is complementary to the Simplexa VZV Direct kit for cerebrospinal fluid samples, as well as Simplexa tests for the herpes simplex virus, which can be difficult to differentiate from the varicella-zoster virus based on clinical signs and symptoms.
December 16, 2019
2019 08 20 21 56 5767 Diasorin Aacc 2019 400
DiaSorin's Simplexa varicella-zoster test gets CE Mark
The assay is used with the Liaison MDX instrument, and it complements the company's Simplexa HSV 1 & 2 Direct kit for the herpes simplex virus (HSV).
September 26, 2019
2019 09 27 20 23 8184 Diasorin Aacc 2019 400
DiaSorin Molecular's Simplexa herpes virus test gets CE Mark
Designed for use with the company’s Liaison MDX thermocycler, the test detects HSV types 1 and 2 and VZV in cutaneous and mucocutaneous swab specimens.
May 15, 2019
2019 05 02 23 38 2538 Check Mark 400
Most Popular
Quest launches long-COVID testing panels for consumers
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Page 1 of 1